|Mr. George Jay Goldsmith||Co-Founder, Chairman & CEO||722.79k||N/A||1954|
|Mr. Lars Christian Wilde||Co-Founder, Pres & Chief Bus. Officer||N/A||N/A||1986|
|Dr. Ekaterina Malievskaia M.D.||Co-Founder, Chief Innovation Officer & Exec. Director||536.4k||N/A||1967|
|Mr. Piers John Morgan ACA, MA||Chief Financial Officer||N/A||N/A||1966|
|Mr. Nathan Poulsen J.D.||Gen. Counsel & Chief Legal Officer||N/A||N/A||1979|
|Mr. Stephen D. Schultz||Sr. VP of Investor Relations||N/A||N/A||N/A|
|Ms. Tracy Cheung||Chief Communications Officer||N/A||N/A||N/A|
|Mr. Marco Mohwinckel||Chief Commercial Officer||N/A||N/A||N/A|
|Mr. Trevor Mill||Chief Devel. Officer||N/A||N/A||N/A|
|Dr. Greg Ryslik Ph.D.||Sr. VP of Data Science, Machine Learning & Digital Health Research||N/A||N/A||N/A|
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
COMPASS Pathways plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.